Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

StatusRecruiting

PhasePhase 2

SponsorH. Lee Moffitt Cancer Center and Research Institute

Started2025-04-01

View on ClinicalTrials.gov ↗

Amendment history

2026-03-31

Study Status v10

Start date2025-03-24→2025-04-01

2026-01-27

3 amendments v7-v9

3 re-verifications since 2025-06-17, no change to tracked fields

2025-04-21

Study Status v6

Start dateestimated 2025-03→confirmed 2025-03-24

2025-03-20

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5

Trial statusNot Yet Recruiting→Recruiting

Study sitesdetails revised at 1 of 1 site

2025-03-14

Study Status v4

Re-verified, no change to tracked fields

Show 3 earlier versions

2025-01-22

Study Status v3

Start date2025-01→2025-03

2024-12-11

Study Status v2

Start date2024-11→2025-01

2024-10-14

Study Status v1

Start date2024-09→2024-11

2024-08-12

Original filing

H. Lee Moffitt Cancer Center and Research Institute

209 trials monitored

See 17 trials at risk

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

Liver Cancer

1,505 trials monitored

See 60 trials at risk

This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.

Trial Details

NCT Number	NCT06553885
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Astellas Pharma Inc
Conditions	Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Enrollment	40 participants
Start Date	2025-04-01
Primary Completion	2029-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-01